Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Correspondence (2)
  7. Conference Paper (1)
Groups
  1. Department of Medicine (292)
  2. Solid Tumor Oncology Division (292)
  3. Thoracic Oncology (292)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (105)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (21)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (85)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC
    Meeting Abstract

    Hayashi, H.; Yu, H. A.; Baik, C.; Kim, D. W.; Johnson, M. L.; Nishio, M.; Yang, J. C. H.; Su, W. C.; Gold, K. A.; Koczywas, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
    Meeting Abstract

    Johnson, M. L.; Jänne, P. A.; Goto, Y.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; Novello, S.; Hayashi, H.; Kim, D. W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor–mutated non–small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy
    Journal Article

    Yu, H. A.; Goto, Y.; Hayashi, H.; Felip, E.; Yang, J. C. H.; Reck, M.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Intracranial outcomes of de novo brain metastases treated with osimertinib alone in patients with newly diagnosed EGFR-mutant NSCLC
    Journal Article

    Imber, B. S.; Sehgal, R.; Saganty, R.; Reiner, A. S.; Ilica, A. T.; Miao, E.; Li, B. T.; Riely, G. J.; Yu, H. A.; Panageas, K. S.; more...
    JTO Clinical and Research Reports (2023)

    Fulltext@MSK | Save
  • Patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01
    Meeting Abstract

    Yu, H. A.; Yasushi, G.; Hidetoshi, H.; Felip, E.; Chih-Hsin Yang, J.; Reck, M.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; more...
    Journal of Oncology Navigation & Survivorship (2023)

    Fulltext@MSK | Save
  • The promise and limitations of neoadjuvant immune-checkpoint blockade in resectable non–small cell lung cancer
    Editorial

    Cooper, A. J.; Yu, H. A.
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Frequency and outcomes of leptomeningeal metastases in patients with fusion-positive lung cancers
    Meeting Abstract

    Chen, M.; Sui, J.; Wilcox, J.; Yang, S. R.; Imber, B.; Offin, M.; Yu, H.; Kris, M. G.; Drilon, A. E.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brain metastases in patients with fusion-positive lung cancers
    Meeting Abstract

    Sui, J. S.; Chen, M. F.; Wilcox, J.; Yang, S. R.; Li, B. T.; Riely, G. J.; Offin, M.; Yu, H. A.; Kris, M. G.; Drilon, A. E.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of patients with EGFR-mutant lung cancer with acquired BRAF alterations
    Meeting Abstract

    Sui, J.; Yang, S. R.; Bowman, A. S.; Vankayala, P.; Falcon, C.; Somwar, R.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Consolidation EGFR-tyrosine kinase inhibitor (TKI)vs. durvalumab vs. observation in unresectable EGFR-mutant stage III NSCLC
    Meeting Abstract

    Nassar, A. H.; Adib, E.; Kaldas, D.; Feng, J.; AbuAli, T.; Aredo, J.; Fitzgerald, B.; Bar, J.; Thummalapalli, R.; Parikh, K.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save